News Center
Research and innovation also speed up the progress bar | Livzon Group JP-1366 Phase III clinical study launched
Release time:
2024-12-09
Research and innovation have also progressed, followingnew drugs with independent intellectual property rightsfor injectionJP-1366The clinical trial application has been accepted by the National Medical Products Administration's Drug Review Centerafter12month5day, the first subject enrollment in the phase III clinical study held by Livzon Group marksJP-1366the research and development of the drug entering a new milestone, promising new options for the treatment of related diseases.JP-1366The drug is an innovative potassium ion competitive acid blocker introduced by BD (
JP-1366)P-CABits active compoundJP-1366, through competitive binding with potassium ionsH+/K+-ATPasereversibly inhibits the proton pump's acid secretion function, resulting in a strong effect of inhibiting gastric acid secretion.The clinical development indication for the drug is reflux esophagitis. Currently, the "Chinese Expert Consensus on Gastroesophageal Reflux Disease in 2021" has listedthe oral formulation as one of the first-choice drugs for reflux esophagitis, with advantages such as rapid onset, excellent acid suppression, long-lasting effects, and few adverse reactions.
JP-1366Innovation is the main lever for high-quality development. Livzon Group has always regarded research and innovation as one of its corporate social responsibilities, focusing on unmet clinical needs, practicing the mission of "patient quality of life first," and continuously providing patients with more high-quality and efficient health solutions.2020年中国胃食管反流病专家共识》已将P-CAB口服剂型作为反流性食管炎的首选药物之一，具有起效快、抑酸效果佳且作用持久、不良反应少等优点。
创新是高质量发展的主要抓手，丽珠集团一直把研发创新作为企业社会责任之一，始终聚焦未被满足的临床需求，践行“患者生命质量第一”的使命，持续为患者提供更多优质、高效的健康解决方案。
Related Information